The Myb-Ets protein encoded by the E26 acute avian leukemia virus is a paradigm for the function of fused transcriptional activator oncoproteins. Myb-Ets transforms hematopoietic progenitor cells (Myb-Ets progenitors, MEPs) that can be induced to differentiate into eosinophilic and myeloid cells by the activation of pathways involving Ras and/or protein kinase C. The Ets portion of the fusion protein seems to be required to maintain the multipotency of MEPs: MEPs transformed with a temperature-sensitive E26 mutant with a lesion in Ets (ts1.1) and shifted to the non-permissive temperature predominantly form erythroid cells, but also form eosinophilic and myeloid cells. This interpretation is complicated, however, by the observation that ts1.1-transformed MEPs differ from MEPs transformed with wild-type E26 in that they express erythroid and eosinophil markers even at the permissive temperature.
Background
A growing number of human neoplasms exhibit specific chromosomal translocations that result in the formation of fused proteins. These fusion proteins often contain parts of transcription factors [1] . One-well studied example of such a fused transcription factor-type oncoprotein is the Myb-Ets protein encoded by the avian E26 retrovirus. Myb and Ets are derived from the helix-turn-helix transcriptional activators c-Myb and c-Ets-1 and, although mutated, have retained their DNA-binding and transactivation domains (for review see [2] ). E26 virus causes an acute leukemia in chickens and transforms hematopoietic progenitors (Myb-Ets progenitors, MEPs) as well as myeloblasts in vivo and in vitro [3] . Both Myb and Ets are required, and must be fused, for leukemogenicity and for in vitro transformation of MEPs; however, the transactivation domain of Ets is dispensable [4] . Although MEPs express surface markers characteristic of thrombocytes, and other markers characteristic of both erythroid and thrombocytic cells, they exhibit properties of multipotent progenitors. Thus, they can be induced to differentiate along the eosinophil and myeloid lineages either by the introduction of v-Ras or kinase-type viral oncogenes, or by the activation of protein kinase C following treatment with the phorbol ester TPA [3, 5, 6] .
Using a temperature-sensitive mutant of E26 with a lesion in the DNA-binding domain of Ets (ts1.1), we previously showed that when ts1.1-transformed MEPs were shifted from 37°C (the permissive temperature) to 42°C (the non-permissive temperature) they differentiate along the erythroid lineage, with some clones also differentiating along the myelomonocytic and eosinophil lineages [6] . Because the in vitro DNA-binding capacity of the Ets domain is inactivated at 42°C [6] , these results suggested that Ets DNA-binding activity of the fusion oncoprotein is required to maintain the multipotency of MEPs. A caveat to this interpretation comes from the observation that a large proportion of ts1.1-transformed MEPs express markers characteristic of erythroid cells and eosinophils even at 37°C, either because the DNA-binding capacity of Ets is weakened at the permissive temperature [6] or because the mutation also affects other functions of the protein. We have therefore introduced the term 'erythroid' or 'E'-MEPs for ts1.1-transformed MEPs to distinguish them from the 'thrombocytic' or 'T'-MEPs transformed by the wild-type E26 virus [5, 7] . Therefore the phenotypic differences between MEPs transformed by E26 and ts1.1 do not allow us to distinguish unambiguously between the possibilities that inactivation of Ets induces the commitment of MEPs or that it merely triggers the maturation of pre-committed erythroid/eosinophil cells.
Here we have re-examined the role of Ets by entirely deleting it from MEPs transformed with Myb-Ets. For this purpose we have developed a novel approach, consisting of the introduction within the retroviral vector of two FLP recombinase recognition sites flanking ets and the inclusion within the same vector of the sequence encoding a hormone-inducible FLP recombinase. The results show that hormone treatment of MEPs transformed by this construct leads to the excision of ets and differentiation of the cells along the erythroid lineage.
Results
We constructed a bicistronic retroviral vector encoding both Gag-Myb-Ets and a fusion protein made up of the yeast FLP recombinase and the hormone-binding domain of the human estrogen receptor (FLP-ER) [8] . In addition, we introduced a minimal FLP recombinase target site in frame between myb and ets and a second minimal target site 3′ to the sequence encoding the recombinase, in a construct called FRV-3 (Fig. 1a) . Once activated by hormone treatment the recombinase should excise the ets and FLP-ER sequences, producing a structure corresponding to the one shown at the bottom of Figure 1a .
To determine whether FRV-3 was capable of transforming hematopoietic cells, 2-day-old chicken embryos, which contain a large number of E26 target cells, were infected with the construct and seeded in semisolid medium at 37°C. The yields of MEPs and myeloblast colonies were similar to those obtained with the wild-type virus. Several MEP-type FRV-3-expressing colonies were isolated one 
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week after infection, expanded in liquid culture and examined for the expression of a battery of lineagerestricted cell-surface markers. They were found to express the thrombocyte-and MEP-restricted MEP21 and MEP26 antigens but none, or very little, of the erythroid antigen JS4 [9] , the eosinophil antigen EOS47 [10, 11] and the myeloid antigen MYL 51/2 [12] . They were therefore indistinguishable from 'T'-MEPs transformed by wildtype virus and clearly different from the 'E'-MEPs transformed by the ts1.1 mutant.
Treatment of FRV-3-transformed MEP clones with either the estrogen agonist ␤-estradiol, or the antagonist ICI 182 780 (ICI), resulted in the appearance of a diagnostic PCR product, following amplification of total genomic DNA with primers flanking the expected recombination junction (Fig. 1a,b ). Cloning and sequencing of this PCR fragment confirmed that the recombinase induced the precise excision of the sequences encoding ets and FLP-ER from the integrated proviral genome. In addition, an 80 kDa Gag-Myb protein was detected in hormonetreated, recombinase-expressing cells, which had resulted from the excision of ets. However, in one particular clone (clone 212), no Gag-Myb protein was detected. Blotting of extracts from this clone with an antibody directed against the human estrogen receptor showed that it no longer expressed FLP-ER (Fig. 1c) .
Concomitant with the loss of Ets, the cells began to express ␣-and ␤-globin mRNA (Fig. 2a) . When tested at the single-cell level, all clones contained hemoglobinpositive cells, ranging from 5 % to 20 % of the total population at day 5 ( Fig. 2b) . A time course of hemoglobin induction showed that the proportion of erythroid cells reached a plateau 5-6 days after initiation of ICI treatment (Fig. 2c ). This plateau probably reflects a balance between recombination-induced, growth-arrested erythrocytes and their continuous replacement by self-renewing MEPs, which have not yet deleted Ets. To show that hormone treatment did not induce erythroid differentiation per se, we treated wild-type MEPs with ␤-estradiol or ICI. Neither of these treatments led to an increase in ␤-globin expression (data not shown).
In parallel with the emergence of hemoglobin-positive cells in FRV-3 transformants, a subpopulation of cells emerged that had lost expression of the cell-surface markers MEP21 (Fig. 3a) and GPIIb-IIIa (a thrombocytespecific integrin also produced by MEP cells [5] ); these cells instead expressed the erythroid marker JS4. The cellsurface expression of the JS4 antigen allowed us to determine whether the erythroid cells specifically lacked Ets, as one might predict if the switch in phenotype was indeed due to the Ets deletion. To this end, ICI-treated FRV-3 transformants were separated into JS4 + and JS4 -fractions by fluorescence-activated cell sorting (FACS; Fig. 3b ) and analyzed for the expression of Myb-containing proteins (Fig. 3c) . JS4 + cells (lane 4) exclusively expressed the Gag-Myb protein, whereas JS4 -cells (lane 3) contained both Gag-Myb-Ets and reduced levels of Gag-Myb protein compared to unsorted cells (lane 2). The unexpected expression of Gag-Myb protein by cells in which no change in phenotype had taken place can be explained by assuming that there are cells present that have already excised Ets, and that these cells still contain sufficient levels of the undegraded Gag-Myb-Ets protein to block maturation. This would also imply that the full-size protein prevents MEPs from becoming erythroid even in the presence of the truncated protein.
To investigate whether the excision of Ets also induces the differentiation of MEPs along the eosinophil and myelomonocytic lineages, 12 clones transformed by FRV-3 were examined for the expression of various lineage-specific cell-surface markers following a 5-day treatment with ICI ( Fig. 4) or ␤-estradiol (data not shown). Whereas all ICI-treated clones contained a subpopulation of JS4 + cells, none contained eosinophils, as detected by a lack of expression of the EOS47 antigen (Fig. 4a ) and eosinophilspecific peroxidase. They also did not contain myelomonocytic marker-positive cells, as detected by using antibodies directed against the MYL 51/2 antigen (Fig. 4) . These two cell types could not be found even when the clones were maintained for up to 12 days in the presence of the inducer (data not shown). Although ets was excised in only a fraction of hormone-treated FRV-3 cells, we think that the absence of detectable eosinophils and myeloblasts is significant, as these cells can proliferate when Ets is inactivated in ts1.1-transformed MEPs [6] and should have a growth advantage relative to the differentiated erythroid cells. To verify that the FRV-3 transformants had not lost their capacity to differentiate, three clones were treated with 20 nM of the phorbol ester TPA. As has been described earlier for MEPs transformed with wild-type E26 [3] , all of the FRV-3-transformed MEP clones that were tested differentiated into eosinophils (Fig. 4b) and into low (but significant) numbers of myeloblasts.
The absence of EOS47-and MYL 51/2-positive cells in ICI-treated FRV3-transformed MEPs might be due to the drug's interference with differentiation along these lineages, rather than a consequence of ets excision. To test this possibility, two multipotent MEP clones transformed with ts1.1 were grown in the presence or absence of ICI at 37°C or 42°C and analyzed at day 6 for their content of EOS47-and MYL 51/2-positive cells. The results in Figure 5 show that ICI does not interfere with differentiation of MEPs along the eosinophil and myeloid lineages, and even slightly enhances eosinophil differentiation. Similarly, when ts1.1 cells were shifted to 42°C for 6 days, the level of erythroid differentiation was increased by ICI and decreased by ␤-estradiol, as measured by benzidine staining and by northern blotting for ␤-globin RNA (F.R. and T.G., unpublished observations).
Discussion
Here, we have demonstrated the feasibility of producing 'conditional' alleles of protein subdomains in a retroviral vector, using a novel approach based on the use of a sitespecific recombinase. The experiments described also unambiguously demonstrate that the removal of Ets from MEPs releases their differentiation block along the erythroid lineage, thus ruling out the outgrowth of pre-committed erythroblasts. Our data support the notion that wild-type E26 virus and ts1.1 transform the same target-cell population and that these cells acquire different phenotypes after transformation. This strongly argues against the possibility that the two viruses transform different targets.
As E26-encoded Myb is, by itself, capable of inducing the formation of large, mature erythroid colonies [13] , the induction of erythroid differentiation in MEPs following Ets excision might reflect a reversal to the phenotype of erythroid cells transformed by v-Myb only. Because our earlier experiments showed that Myb and Ets efficiently transform erythroid cells [13] , the targeting technology involving the FLP recombinase target site and the FLP-ER fusion protein should now make it feasible to determine whether rejoining Gag-Myb with Ets in erythroblasts transformed by the two separately expressed oncoproteins will force them to acquire MEP properties.
A comparison with the results obtained with MEPs transformed by the ts1.1 mutant of E26 indicate that the Ets portion of the fused oncoprotein has multiple functions in immature hematopoietic cells. Thus, whereas MEPs transformed by wild-type E26 virus or by FRV-3 are tightly blocked in their differentiation program, ts1.1-transformed MEPs differentiate partially along the erythroid and eosinophilic lineage at 37°C and essentially completely at 42°C. The findings that the in vitro DNAbinding capacity of the ts1.1 Ets DNA-binding domain is weakened at room temperature and completely abolished at 42°C [6] , and that hormone-treated FRV-3-transformed MEPs also differentiate along the erythroid lineage following loss of Ets, suggest that commitment to erythroid differentiation requires the DNA-binding capacity of Ets. In contrast, the finding that ts1.1-transformed MEPs undergo eosinophil and myeloid differentiation upon temperature shift, but that MEPs from which Ets is deleted do not, suggests that Ets also has a DNA-independent function that is required for maturation along these lineages. As hormone-treated FRV-3-transformed MEPs do not generate detectable numbers of myeloid cells, one can speculate that a similar DNA-binding-independent function of Ets is required for myeloid differentiation. This explanation is, however, weakened by the following three observations: first, not all ts1.1-transformed MEPs can be induced to differentiate along the myeloid lineage [6] ; second, Ets could only be deleted from a fraction of FRV-3-transformed MEPs; and third, the induction of myeloid differentiation in FRV-3-transformed MEPs by TPA treatment was found to be inefficient.
A possible DNA-independent function of Ets in eosinophil differentiation could be to recruit one or more nuclear protein(s) to Myb-Ets-bound promoters; these proteins might modify the spectrum of target genes regulated by the oncoprotein. This model is in part supported by our recent identification of MafB, a bZip (basic region-leucine zipper) transcription factor that binds to c-Ets-1 [14] . Whether or not MafB plays a role in lineage commitment remains to be determined. Such a model is analogous to the one proposed for the function of the E2a-Pbx fusion oncoprotein that has been implicated in human B-cell leukemia. In this chimeric transcription factor, the DNAbinding domain of the homeodomain-containing Pbx protein is dispensable for cell transformation. Instead, Pbx is thought to modify the DNA-binding capacity of the helix-loop-helix E2a protein by recruiting other homeodomain proteins to the promoter complex [15] [16] [17] .
Retroviral vectors exploiting inducible recombination strategies offer a powerful tool for the study of protein function by allowing deletion of an entire protein or specific protein domains in live cells. This represents an alternative to inactivating gene function by using temperature-sensitive mutants and offers the advantages of rational design and unequivocal result interpretation. Our data also illustrate the power of comparing both approaches. The potential limitation of FLP-mediated gene excision might be overcome by using drug-resistance markers, allowing the selection of cells in which recombination has taken place, and by developing more efficiently inducible FLP vectors (P.-O. Angrand, M. Nichols, C.L., F.R. and A.F.S., unpublished observations) or CRE vectors [18] . Such improvements to the retroviral oncogene-recombinase approach may have more general applications, including in gene therapy. Here it might become possible to first expand cells through oncogene transformation and then 'normalize' them through oncogene excision.
Materials and methods

Viral constructs
FRV-3 was engineered to contain two modified minimal recombinase target sites of 39 nucleotides flanking the 5′ end of the ets gene and the 3′ end of the sequence encoding FLP-ER. The 5′ minimal target site encodes 13 novel amino acids between positions 32 and 33 of Ets, in a region which has been shown to be dispensable for MEP cell transformation [4] . To obtain FRV-3, an oligonucleotide corresponding to a minimal FLP target site (mFRT, CTAGAGAAGTTCCTATACTCTAG-TAAGAATAGGAACTTCGAAGA) was inserted at the XbaI site at position 11 799 of pMI3-IRES. pMI3-IRES was obtained by cloning the PvuII fragment encoding the encephalomyocarditis internal ribosome entry site (IRES) from the plasmid pCITE2a (Novagen) in the blunted Asp718 site at position 11 025 of pMI3; pM13 is an E26 virus with a modified LTR sequence [19] . A second mFRT oligonucleotide (CTAGTTCGAAGTTCCTATTCTCTAGTAAGTATAGGAACTTCT) was inserted at the NheI site at position 9 425 of pMI3-IRES. To minimize the size of the recombinase target site insertion, two of the three repeats present in the wild-type target site were used [20, 21] . The FLP-ER gene was inserted as a NcoI-NotI fragment in the polylinker 3′ of IRES. The NcoI site was introduced into the FLP gene by PCR, resulting in a Pro to Ala change at position 2 of the recombinase amino-acid sequence.
Cells
All cells were derived from embryos of a White Leghorn chicken flock maintained by Lohmann and Co., Cuxhaven, Germany. The Q2bn packaging cell line [22] was grown in Dulbecco's modified Eagle's medium containing 8 % fetal calf serum, 2 % chicken serum and 10 mM Hepes. Transformed primary cells were grown in 'blastoderm medium' [3] with or without approximately 10 U ml -1 crude cMGF [23] .
Production of infectious virus and blastoderm transformation assay
Blastoderm cells were obtained from 2-day-old chick embryos (stage 10-12) as previously described [3] . Viruses were produced by transiently transfecting plasmids containing proviral sequences in the Q2bn packaging cell line [22] by Ca 3 (PO 4 ) 2 precipitation. For infection, pools of 2-day-old chicken embryo cells were cocultivated with mitomycin-C-treated, transfected Q2bn cells for 24 h, the non-adherent cells removed and plated in 0.8 % methylcellulose-containing blastoderm medium. After 10 days, transformed colonies were picked and expanded in liquid medium.
Antibodies and immunofluorescence
Mouse monoclonal antibodies directed against MEP21 [3, 10] , EOS47 [10, 11] , MYL 51/2 [12] were produced in this laboratory. The JS4 antibody was described by Schmidt et al. [9] and provided by H. Beug. The EF-3 antibody directed against the human estrogen receptor [24] was a kind gift from H. Gronemeyer and P. Chambon. Indirect immunofluorescence was performed on living cells. Cells were incubated for 10-30 min with the first antibody, washed in medium, centrifuged as described above and resuspended with fluorescein-labeled goat antimouse second antibody. After an additional 10-30 min incubation, cells were washed twice, and resuspended in medium containing propidium iodide at a final concentration of 5 g ml -1 . Samples were analyzed on a Beckman FACScan fluorocytometer using live gating to exclude dead cells. Cell sorting was performed with a Coulter Epics sorter.
Western blotting
Cells were lysed in a solution containing 0.1 % Triton X-100, 25 mM Tris-HCl (pH 7.6), 1 mM EDTA (pH 8), 200 mM NaCl, 50 mM NaF, 0.1 mg ml -1 leupeptin, 1 mM PMSF and 1 % Trasylol (Bayer), the extracts fractionated by SDS-PAGE and blotted onto Immobilon-P membrane (Millipore). Immunodetection was performed by enhanced chemiluminescence (ECL; Amersham) as recommended by the manufacturer.
